Epithelioid
Hormonal Status May Contribute to Sex-Based Survival Differences in Epithelioid Peritoneal Mesothelioma
Annals of Surgical Oncology 2026 March 12 [Link] Kaelyn C Cummins, Olivia Sears, Elio R Bitar, Chengli Shen, Allan Tsung, Samantha M Ruff Abstract Background: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is central to treating patients with epithelioid peritoneal mesothelioma (EPM). Male sex is a negative prognostic factor in mesothelioma, but the reasons…
Read MoreMalignant Pleural Mesothelioma (MPM) Evaluation with [11C]-Methionine PET/CT Before and After Talc Pleurodesis
Molecular Imaging and Biology 2026 March 9 [Link] Egesta Lopci, Angelo Castello, Alberto Testori, Emanuele Voulaz, Daoud Rahal 5, Matteo Perrino 6, Alessandro Crepaldi 3, Giorgio Maria Ferraroli 3, Valentina Errico 3, Edoardo Bottoni 3, Marcello Rodari 7, Lorenzo Muraglia 2, Giuseppe Marulli 3 4, Marco Alloisio, Paolo Andrea Zucali Abstract Background: Malignant pleural mesothelioma…
Read MorePleural Fluid Cytology-Histology Correlation in Patients With Malignant Pleural Mesothelioma: A Series of 26 Cases
Cytopathology 2026 February 20 [Link] John Findley, Matthew Demetrious, Lucas Yan, Lei Yan Abstract Background: To understand the efficacy of pleural effusion cytology in the diagnosis of malignant mesothelioma, we conducted this retrospective study to review the pleural fluid cytologies of patients diagnosed on concurrent/recent pleural biopsy histology. The clinicopathologic features and common cytomorphology were…
Read MoreBAP-1 in the diagnosis of malignant pleural mesothelioma
Respiratory Medicine and Research 2025 November 28 [Link] Irene Sansano, Ana Vázquez, Oscar Persiva, Marc Simó, Leire Sánchez, Pilar Montoya, Carme Dinarès, Carmen Alemán Abstract Background: The diagnosis of malignant pleural mesothelioma (MPM) can be challenging for clinicians and pathologists. Patients and methods: This study included all patients diagnosed with pleural mesothelioma between October 2013…
Read MoreConstruction and validation of a prognostic risk score model for malignant mesothelioma
Discover Oncology 2026 February 8 [Link] Qingzheng An, Fengyun Cui, Guangming Shi, Longkun Ni, Kun Xiao, Feng Tian, Yuezhi Chen, Leping Li, Changqing Jing, Guodong Lian Abstract Purpose: Malignant mesothelioma is a rare, aggressive cancer. Although the World Health Organization (WHO) histologic subtypes–epithelioid (best prognosis), biphasic, and sarcomatoid (worst prognosis)—provide baseline stratification, architectural and molecular…
Read MoreDisaster on MARS2? Lessons Learned from Modern Day Outcomes of Surgery for Pleural Mesothelioma
The Annals of Thoracic Surgery 2026 February 2 [Link] Shubham Gulati, Andrea Wolf, Jai Mehrotra-Varma, Stephanie Tuminello, Emanuela Taioli, Raja Flores Abstract Background: The Mesothelioma and Radical Surgery 2 (MARS2) trial has drawn into question pleurectomy/decortication (PD) for the treatment of pleural mesothelioma. This trial’s evaluation of resectability (poor positron emission tomography/computed tomography utilization, patients…
Read MoreEpithelioid Mesothelioma Cells Exhibit Increased Ferroptosis Sensitivity Compared to Non-Epithelioid Mesothelioma Cells
Cancers 2025 December 13 [Link] Tatsuhiro Sato, Ikue Hasegawa, Haruna Ikeda, Taichi Ohshiro, Lisa Kondo-Ida, Satomi Mukai, Satoshi Ohte, Tohru Maeda, Yoshitaka Sekido Abstract Background/Objectives: Mesothelioma is a highly aggressive tumor with a poor prognosis that typically develops after a long latency period following asbestos exposure. Although immunotherapy combined with chemotherapy is increasingly used, the…
Read MoreDeterminants of Response to Immune Checkpoint Blockade in Pleural Mesothelioma: Molecular, Immunological, and Clinical Perspectives
Cancers 2025 December 17 [Link] Martina Delsignore, Gaia Cassinari, Simona Revello, Luigi Cerbone, Federica Grosso, Marcello Arsura, Chiara Porta Abstract Diffuse pleural mesothelioma (PM) is a rare thoracic malignancy with historically limited treatment options and poor outcomes. Despite the recent breakthrough of dual immune checkpoint blockade (ICB)-notably the combination of anti-PD-1 and anti-CTLA-4 therapies-clinical responses…
Read MoreMerlin Immunohistochemistry Is Useful in the Differential Diagnosis of Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia
Pathology International 2026 January [Link] Kohei Aoe, Kei Kushitani, Vishwa Jeet Amatya, Tetsuya Nakagiri, Yoshihiro Miyata, Morihito Okada, Yukio Takeshima Abstract The differential diagnosis of epithelioid mesothelioma and reactive mesothelial hyperplasia can be challenging based on morphology alone, particularly in small specimens. Consequently, the use of ancillary techniques, such as immunohistochemistry for BRCA1-associated protein 1,…
Read MoreDiagnostic potential of a novel immunohistochemical marker, GFPT2, in differentiating mesothelioma from its morphological mimics
Histopathology 2025 December 15 [Link] Jia Wei, Xiaofang Ma, Gang Chen, Yan Wang, Qinhe Fan, Qixing Gong Abstract Aims: Mesothelioma (MESO) is a rare and aggressive tumour originating from mesothelial cells, primarily affecting the pleura and peritoneum. Its diagnosis remains challenging due to non-specific clinical, radiological and histopathological features, compounded by morphological diversity and overlapping…
Read More
Skip to content